Name: Mingyan Xu

Country: China

Affiliation:

CEO & Founder of HaploX

Phone no: +86) 185 7569 5023

Email: Send an Email


Address:

8F Auto Electric Power Building, 3 Songpingshan Road, Nanshan District, Shenzhen, Guangdong, China 518057

Research Interests:

  • Biotechnology, 
  • DNA sequencing,
  •  Genomics, 
  • Synthetic Biology, 
  • cancer biology,
  •  radiopharmaceuticals

Biography:

  • CEO&Founder of Haplox Biotechnology (Shenzhen) co., LtD Aug. 2014-present
  •  Staff Scientist at Cambrian Genomics Inc. USA Jan. 2013-July 2014
  •  DNA laser printing technology
  •  Lead to a revolution of synthetic biology by providing multiplex parallel-synthesized gene size DNA oligonucleotides for lower cost, higher accuracy, and higher throughput.
  •  Leveraged Next-Generation Sequencing technology to invent the first DNA recoverable sequencer in the world for DNA Laser Printing. 
  • Research Assistant at Univ. of New Mexico 
  • Aug. 2008-July 2013‚• Led the ‘Polony Sequencing and the $1,000 Genome’ project funded by NIH to Jeremy S. Edwards ($3 Million). Invented Rolony (Rolling Circle amplified Colony) sequencing by ligation (Collaborated with George M. Church Lab at Harvard Medical School) and by synthesis (SBL and SBS) on Polonator G.007 and MINI-20/GeneReader (Qiagen)
  • Developed NGS applications on Preimplantation Genetic Diagnosis and Screening (PGD/PGS), tumor early diagnosis, monitoring and drug-resistant evaluation.
  • Invented Haplotype-Resolved Sequencing technology to directly measure haplotype information unprecedentedly.
  •  Firstly developed Dual Primer emulsion PCR (DPePCR) technology for Polony Sequencing.
  •  Extensive experience on MiSeq, Hiseq2000/2500 (Illumina), Polonator G.007, Ion PGM/Proton, MINI-20/GeneReader Next-generation Sequencers.
  •  Extensive experience with different NGS sample preparation methods and protocols. Familiar with Bowtie/Bowtie2, SAMtools, CLCBio, Golden Helix, etc. Open source and commercial NGS data analysis tools. 2 Quality Controller at Beijing Shihong Pharmaceuticals Sept. 2005-June 2008
  •  Quality control of a serial of pharmaceuticals, i.e., [ 99mTc]-MIBI, [ 99mTc] technetepyrophosphate, [ 99mTc]-Pentetate, [ 99mTc]- MAA, etc.
  • Synthesized more than 500GRAM of hexakis-2-methoxyisobutylisonitrile (MIBI), which can supply the China market for at least 10 years.
  •  Extensive experience on manufactory pipeline of radiopharmaceuticals, including organic synthesis, kit recipe development, and sample sterilized distribution, cryodesiccation, radio labeling, quality control, etc.